查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1907959

异种移植市场：依异种移植类型、动物来源物种、应用、器官类型、免疫抑制通讯协定、最终使用者和地区划分

Xenotransplantation Market, By Type of Xenotransplantation, By Source Animal Species, By Application, By Type of Organ, By Immunosuppressive Protocols, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3个工作天内

价格
简介目录

异种移植市场预计在 2026 年达到 32.1 亿美元，预计到 2033 年将达到 62.2 亿美元，2026 年至 2033 年的复合年增长率为 9.95%。

分析范围 分析详情
基准年 2025 市场规模（2025 年） 32.1亿美元
效能数据 2021-2024 预测期 2026-2033
预测期（2025-2032 年）复合年增长率 9.90% 预计金额（2032 年） 62.2亿美元

全球异种移植市场代表着移植医学领域的创新前沿，它透过将基因改造的动物器官（主要来自猪）移植到人类受体体内，来解决人类器官严重短缺的问题。这个新兴领域结合了先进的基因工程技术（包括CRISPR-Cas9基因编辑）和精密的免疫抑制疗法，以克服物种特异性的生物屏障和免疫排斥机制。

异种移植涵盖多种器官类型，包括心臟、肾臟、肝臟、肺臟和胰岛，为全球数百万末期器官衰竭患者提供了潜在的解决方案。该市场涉及众多相关人员，包括专注于基因改造的生物技术公司、开发免疫抑制通讯协定的製药企业、开展临床前和临床试验的研究机构以及製定安全框架的监管机构。近期的突破性进展，例如在临床环境中成功进行的猪到人的心臟和肾臟移植，证明了这项技术的可行性，同时也凸显了持续研发的必要性。该市场的特点是对基因工程平台、无病原体供体动物的研发以及器官保存技术的进步进行了大量投资。

市场动态

全球异种移植市场的主要驱动力是人类器官捐赠者的严重短缺。目前，超过10万美国人在器官移植等待名单上，但每年只有一小部分人能够接受移植手术。这种情况使得寻找替代器官来源的需求变得迫切。基因工程技术的进步，特别是CRISPR-Cas9等基因编辑工具的应用，使得对供体动物进行精确改造，从而降低免疫抗原性并提高与人类生理的相容性成为可能，进而推动了市场成长。包括心血管疾病、慢性肾臟病和糖尿病併发症在内的终末期器官疾病的日益普遍，以及全球人口老化，都显着扩大了需要器官移植的潜在患者群体。

生技公司、创业投资和政府资助机构的大量投资支持了广泛的研发活动，这些活动正在推动基因修饰技术、免疫抑制疗法和器官保存方法的创新。

然而，该市场面临诸多限制因素。复杂的法规结构要求在临床应用前进行广泛的安全性和有效性测试，这可能会使市场准入延迟数年。此外，动物福利方面的伦理问题、宗教敏感性以及社会对动物性器官移植的低接受度也阻碍了其广泛应用。通用感染疾病传播的风险，包括猪内源性逆转录病毒和其他人畜共通病原体，需要全面的筛检通讯协定和长期的安全监测，这增加了研发成本和监管复杂性。

然而，发展中国家医疗保健支出的成长、对先进医疗技术的接受度提高以及生物技术公司与学术研究机构之间潜在的合作，正在催生新的机会。标准化监管流程的建立、成功的临床试验以及无病原体动物饲养设施的进步，为市场扩张和商业性可行性提供了巨大的成长机会。

本报告的主要特点

  • 本报告对全球异种移植市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
  • 它还重点介绍了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的关键见解。
  • 根据公司概况、产品系列、主要亮点、财务表现和策略等参数，对全球异种移植市场的主要企业进行了分析。
  • 本报告提供的见解将使负责人和公司经营团队能够就未来的产品发布、产品更新、市场扩张和行销策略做出明智的决策。
  • 《全球异种移植市场》报告涵盖了该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员可以透过用于分析全球异种移植市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章 分析目标与先决条件

  • 分析目的
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要

第三章：市场动态、监管与趋势分析

  • 市场动态
  • 司机
  • 抑制因素
  • 机会
  • 影响分析
  • 重大进展
  • 监管情景
  • 产品上市/核准
  • PEST分析
  • 波特五力分析
  • 企业合併情景
  • 产业趋势

4. 全球异种移植市场（依异种移植类型划分）（2021-2033 年）

  • 固态器官异种移植
  • 细胞异种移植
  • 组织异种移植

5. 全球异种移植市场（依动物来源物种划分）（2021-2033 年）

  • 猪
  • 非人灵长类动物
  • 其他（例如绵羊、牛）

6. 全球异种移植市场按应用领域划分（2021-2033 年）

  • 器官移植
  • 细胞/组织移植
  • 基因编辑应用
  • 再生医学

7. 全球异种移植市场（按器官类型划分）（2021-2033 年）

  • 心
  • 肾
  • 肝
  • 肺
  • 胰臟
  • 皮肤
  • 角膜

8. 全球异种移植市场（依免疫抑制通讯协定）（2021-2033 年）

  • 免疫抑制剂
  • 基因编辑以改变免疫反应
  • 植入前基因改造

9. 全球异种移植市场（以最终用户划分）（2021-2033 年）

  • 医院
  • 研究所
  • 生物技术和製药公司

第十章 全球异种移植市场（按地区划分）（2021-2033 年）

  • 北美洲
    • 美国
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲国家
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 义大利
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 亚太其他地区
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东国家
  • 非洲
    • 南非
    • 北非
    • 中非

第十一章 竞争格局

  • United Therapeutics Corporation
  • eGenesis, Inc.
  • Novartis AG
  • Hoffmanna€'La Roche Ltd.
  • Astellas Pharma, Inc.
  • Preservation Solutions, Inc.
  • OrganOX Limited
  • TransMedic, Pte. Ltd.
  • Pfizer, Inc.
  • Makana Therapeutics
  • Veloxis Pharmaceuticals, Inc.
  • Bio Med Pvt. Ltd.
  • United Therapeutics'Revivicor division
  • Bristola€'Myers Squibb Company
  • NZeno/Nzeno

第十二章 分析师建议

  • 机会
  • 分析师观点
  • Coherent Opportunity Map (COM)

第十三章 参考文献与分析方法

  • 参考
  • 分析方法
  • 关于 Coherent Market Insights
简介目录
Product Code: CMI9142

Xenotransplantation Market is estimated to be valued at USD 3.21 Bn in 2026 and is expected to reach USD 6.22 Bn by 2033, expanding at a compound annual growth rate (CAGR) of 9.9% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2025: USD 3.21 Bn
Historical Data for: 2021 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2025 to 2032 CAGR: 9.90% 2032 Value Projection: USD 6.22 Bn

The global xenotransplantation market represents a revolutionary frontier in transplantation medicine, addressing the critical shortage of human organs through the use of genetically modified animal organs, primarily from pigs, for transplantation into human recipients. This emerging field combines advanced genetic engineering technologies, including CRISPR-Cas9 gene editing, with sophisticated immunosuppressive therapies to overcome species-specific biological barriers and immune rejection mechanisms.

Xenotransplantation encompasses various organ types including hearts, kidneys, livers, lungs, and pancreatic islets, offering potential solutions for millions of patients worldwide suffering from end-stage organ failure. The market encompasses multiple stakeholders including biotechnology companies specializing in genetic modification, pharmaceutical manufacturers developing immunosuppressive protocols, research institutions conducting preclinical and clinical trials, and regulatory bodies establishing safety frameworks. Recent breakthrough achievements, such as successful pig-to-human heart and kidney transplantations in clinical settings, have demonstrated the feasibility of this technology while highlighting the need for continued research and development. The market is characterized by substantial investments in genetic engineering platforms, development of pathogen-free donor animals, and advancement of organ preservation technologies.

Market Dynamics

The global xenotransplantation market is primarily driven by the severe shortage of human organ donors, with over 100,000 Americans currently on organ waiting lists and only a fraction receiving transplants annually, creating an urgent need for alternative organ sources. Advancing genetic engineering technologies, particularly CRISPR-Cas9 and other gene editing tools, enable precise modification of donor animals to reduce immunogenicity and improve compatibility with human physiology, accelerating market growth. Rising prevalence of end-stage organ diseases, including cardiovascular disorders, chronic kidney disease, and diabetes-related complications, coupled with aging global populations, significantly expands the potential patient pool requiring transplantation solutions.

Substantial investments from biotechnology companies, venture capital firms, and government funding agencies support extensive research and development activities, fostering innovation in genetic modification techniques, immunosuppressive therapies, and organ preservation methods.

However, the market faces significant restraints including complex regulatory frameworks requiring extensive safety and efficacy studies before clinical implementation, potentially delaying market entry by several years. Ethical concerns regarding animal welfare, religious considerations, and public acceptance of animal-to-human organ transplantation create additional barriers to widespread adoption. Risk of cross-species disease transmission, including porcine endogenous retroviruses and other zoonotic pathogens, necessitates comprehensive screening protocols and long-term safety monitoring, increasing development costs and regulatory complexity.

Nevertheless, opportunities emerge from increasing healthcare expenditure in developing regions, growing acceptance of advanced medical technologies, and potential partnerships between biotechnology companies and academic research institutions. The development of standardized regulatory pathways, successful clinical trial outcomes, and advancement in pathogen-free animal breeding facilities present substantial growth opportunities for market expansion and commercial viability.

Key Features of the Study

  • This report provides in-depth analysis of the global xenotransplantation market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global xenotransplantation market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include United Therapeutics Corporation, eGenesis, Inc., Novartis AG, F. Hoffmann La Roche Ltd., Astellas Pharma, Inc., Preservation Solutions, Inc., OrganOX Limited, TransMedic, Pte. Ltd., Pfizer, Inc., Makana Therapeutics, Veloxis Pharmaceuticals, Inc., Bio Med Pvt. Ltd., United Therapeutics' Revivicor division, Bristol Myers Squibb Company, and NZeno/Nzeno
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global xenotransplantation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global xenotransplantation market

Market Segmentation

  • Type of Xenotransplantation Insights (Revenue, USD Bn, 2021 - 2033)
    • Solid Organ Xenotransplantation
    • Cellular Xenotransplantation
    • Tissue Xenotransplantation
  • Source Animal Species Insights (Revenue, USD Bn, 2021 - 2033)
    • Pigs
    • Non-human Primates
    • Others (e.g., Sheep, Cows)
  • Application Insights (Revenue, USD Bn, 2021 - 2033)
    • Organ Transplantation
    • Cell and Tissue Transplantation
    • Gene Editing Applications
    • Regenerative Medicine
  • Type of Organ Insights (Revenue, USD Bn, 2021 - 2033)
    • Heart
    • Kidney
    • Liver
    • Lungs
    • Pancreas
    • Skin
    • Cornea
  • Immunosuppressive Protocols Insights (Revenue, USD Bn, 2021 - 2033)
    • Immunosuppressive Drugs
    • Gene Editing to Modify Immune Response
    • Pre-transplantation Genetic Modifications
  • End User Insights (Revenue, USD Bn, 2021 - 2033)
    • Hospitals
    • Research Institutions
    • Biotechnology and Pharmaceutical Companie
  • Regional Insights (Revenue, USD Bn, 2021 - 2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • United Therapeutics Corporation
    • eGenesis, Inc.
    • Novartis AG
    • Hoffmann La Roche Ltd.
    • Astellas Pharma, Inc.
    • Preservation Solutions, Inc.
    • OrganOX Limited
    • TransMedic, Pte. Ltd.
    • Pfizer, Inc.
    • Makana Therapeutics
    • Veloxis Pharmaceuticals, Inc.
    • Bio Med Pvt. Ltd.
    • United Therapeutics' Revivicor division
    • Bristol Myers Squibb Company
    • NZeno/Nzeno

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Xenotransplantation Market, By Type of Xenotransplantation
    • Global Xenotransplantation Market, By Source Animal Species
    • Global Xenotransplantation Market, By Application
    • Global Xenotransplantation Market, By Type of Organ
    • Global Xenotransplantation Market, By Immunosuppressive Protocols
    • Global Xenotransplantation Market, By End User
    • Global Xenotransplantation Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Xenotransplantation Market, By Type of Xenotransplantation, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Solid Organ Xenotransplantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Cellular Xenotransplantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Tissue Xenotransplantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Xenotransplantation Market, By Source Animal Species, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Pigs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Non-human Primates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Others (e.g., Sheep, Cows)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Xenotransplantation Market, By Application, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Organ Transplantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Cell and Tissue Transplantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Gene Editing Applications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Regenerative Medicine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Xenotransplantation Market, By Type of Organ, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Heart
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Kidney
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Liver
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Lungs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Pancreas
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Skin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Cornea
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. Global Xenotransplantation Market, By Immunosuppressive Protocols, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Immunosuppressive Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Gene Editing to Modify Immune Response
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Pre-transplantation Genetic Modifications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

9. Global Xenotransplantation Market, By End User, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Research Institutions
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Biotechnology and Pharmaceutical Companie
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

10. Global Xenotransplantation Market, By Region, 2021 - 2033, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2026,2029 & 2033, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type of Xenotransplantation, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Source Animal Species, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Type of Organ, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Immunosuppressive Protocols, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type of Xenotransplantation, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Source Animal Species, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Type of Organ, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Immunosuppressive Protocols, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type of Xenotransplantation, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Source Animal Species, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Type of Organ, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Immunosuppressive Protocols, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type of Xenotransplantation, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Source Animal Species, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Type of Organ, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Immunosuppressive Protocols, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type of Xenotransplantation, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Source Animal Species, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Type of Organ, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Immunosuppressive Protocols, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type of Xenotransplantation, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Source Animal Species, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Type of Organ, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Immunosuppressive Protocols, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

11. Competitive Landscape

  • United Therapeutics Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • eGenesis, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hoffmanna€'La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Preservation Solutions, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • OrganOX Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • TransMedic, Pte. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Makana Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Veloxis Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bio Med Pvt. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • United Therapeutics' Revivicor division
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristola€'Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NZeno/Nzeno
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

12. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

13. References and Research Methodology

  • References
  • Research Methodology
  • About us